CRDL Q2 EPS Forecast Lowered by Brookline Capital Markets

Cardiol Therapeutics Inc. (NASDAQ:CRDL) – Stock analysts at Brookline Capital Markets decreased their Q2 2026 earnings per share (EPS) estimates for shares of Cardiol Therapeutics in a note issued to investors on Tuesday, May 12th. Brookline Capital Markets analyst F. Ahmed now forecasts that the company will earn ($0.09) per share for the quarter, down from their previous forecast of ($0.07). The consensus estimate for Cardiol Therapeutics’ current full-year earnings is ($0.28) per share. Brookline Capital Markets also issued estimates for Cardiol Therapeutics’ Q3 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.10) EPS and FY2026 earnings at ($0.36) EPS.

CRDL has been the subject of several other reports. Wall Street Zen raised Cardiol Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, April 5th. raised shares of Cardiol Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 3rd. HC Wainwright restated a “buy” rating and issued a $9.00 price objective on shares of Cardiol Therapeutics in a report on Tuesday, February 10th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $8.00 target price on shares of Cardiol Therapeutics in a report on Monday, April 6th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $8.50.

Cardiol Therapeutics Trading Up 0.7%

CRDL stock opened at $1.37 on Friday. The business’s fifty day moving average price is $1.26 and its 200 day moving average price is $1.10. Cardiol Therapeutics has a 12-month low of $0.88 and a 12-month high of $1.71. The company has a market capitalization of $153.19 million, a PE ratio of -4.89 and a beta of 0.77.

Cardiol Therapeutics (NASDAQ:CRDL) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.07) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.07).

Institutional Trading of Cardiol Therapeutics

A number of large investors have recently bought and sold shares of CRDL. Bank of America Corp DE grew its holdings in shares of Cardiol Therapeutics by 136.2% during the second quarter. Bank of America Corp DE now owns 26,455 shares of the company’s stock worth $36,000 after buying an additional 15,255 shares during the last quarter. Two Sigma Investments LP acquired a new stake in shares of Cardiol Therapeutics in the 3rd quarter valued at approximately $249,000. Virtu Financial LLC purchased a new stake in shares of Cardiol Therapeutics in the third quarter valued at approximately $154,000. Citadel Advisors LLC grew its holdings in Cardiol Therapeutics by 1,132.6% during the third quarter. Citadel Advisors LLC now owns 463,462 shares of the company’s stock worth $496,000 after acquiring an additional 425,862 shares during the period. Finally, Susquehanna International Group LLP raised its position in Cardiol Therapeutics by 366.5% in the third quarter. Susquehanna International Group LLP now owns 93,398 shares of the company’s stock worth $100,000 after acquiring an additional 73,375 shares in the last quarter. Institutional investors and hedge funds own 12.49% of the company’s stock.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc (NASDAQ: CRDL) is a clinical-stage pharmaceutical company dedicated to developing immunomodulatory treatments for patients with cardiovascular disease. The company’s lead asset, CardiolRx, is a proprietary, pharmaceutical-grade cannabidiol (CBD) formulation designed to target the inflammation and oxidative stress underlying conditions such as acute myocardial injury and heart failure. Cardiol holds exclusive global rights to CardiolRx through a licensing partnership and is advancing additional preclinical programs focused on small-molecule immunotherapies for heart disease.

CardiolRx is formulated for oral administration and has been evaluated in a randomized, placebo-controlled Phase 2 myocardial protection study assessing safety and key biomarkers following acute coronary syndromes.